Binimetinib

CAS号

606143-89-9

分子式

C17H15BrF2N4O3

主要靶点

MEK|Autophagy

仅限科研使用

Cat No : CM05051

Print datasheet

Synonyms

inhibit|ARRY 162|ARRY 438162|ARRY162|ARRY-162|ARRY438162|ARRY-438162|Binimetinib|Autophagy|MEK|MEK 162|MEK162|MEK-162|Mitogen-activated protein kinase kinase|MAPKK|MAP2K|Inhibitor



产品信息

CAS号 606143-89-9
分子式 C17H15BrF2N4O3
主要靶点 MEK|Autophagy
主要通路 MAPK 信号通路|自噬
分子量 441.23
纯度 100%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
别名 inhibit|ARRY 162|ARRY 438162|ARRY162|ARRY-162|ARRY438162|ARRY-438162|Binimetinib|Autophagy|MEK|MEK 162|MEK162|MEK-162|Mitogen-activated protein kinase kinase|MAPKK|MAP2K|Inhibitor

靶点活性

MEK:12 nM

体内活性

方法:为检测体内抗肿瘤活性,将 Binimetinib (5 mg/kg) 和 BMK120 (7.5 mg/kg) 灌胃给药给携带 A549 异种移植物的 athymic (nu/nu) 小鼠,每天一次,持续 21 天。 结果:单独使用测试剂量的 Binimetinib 和 BKM120 仅对 A549 异种移植物的生长有微弱的抑制作用,但 Binimetinib 与 BKM120 的组合显著抑制了 A549 异种移动物的生长。[2]

体外活性

方法:神经母细胞瘤细胞用 Binimetinib (0-2 μM) 处理 24-120 h,通过 MTT assay 检测细胞活力。 结果:CHP-212、SK-N-BE、SK-N-AS 和 SJ-NB-10 四种细胞系对 Binimetinib 敏感,在治疗 24-120 h 后达到 <50%的存活率,而五种细胞系则对该药物产生耐药性。[1] 方法:NSCLC 细胞 A549、H157 和 H522 用 Binimetinib (0.5-1 μM) 处理 48 h,通过 flow cytometry 检测细胞周期。 结果:在相对较低浓度范围内,例如 0.5 和 1 μM,Binimetinib 在三种敏感的 NSCLC 细胞系中诱导 G1 期阻滞。[2]

溶解度

DMSO:50 mg/mL (113.32 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

细胞实验

MEK162 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[2]. MCF7 cells infected as indicated are seeded in 12-well plates (2×104). After 24 hours, cells are treated with BEZ235 (100 or 200 nM), BKM120 (0.75 or 1 μM), GDC-0941 (1 μM), or MK2206 (2 μM) alone or in combination with MEK162 (1 μM), BI-D1870 (10 μM), or AZD6244 (1 μM), as indicated in text. Cell numbers are quantified by fixing cells with 4% glutaraldehyde or methanol, washing the cells twice in Water, and staining the cells with 0.1% crystal violet. The dye is subsequently extracted with 10% acetic acid, and its absorbance is determined (570 nm). Growth curves are performed in triplicate. Viability assays with CellTiter-Glo are performed by plating 2,000 cells in 96-well plates, adding the drug at 24 hours, and assaying 4 to 5 days after drug addition. Cell-cycle and hypodiploid apoptotic cells are quantified by flow cytometry. Briefly, cells are washed with PBS, fixed in cold 70% ethanol, and then stained with propidium iodide while being treated with RNase. Quantitative analysis of sub-G1 cells is carried out in a FACScalibur cytometer using Cell Quest software[2].

参考文献

1.Woodfield SE, et al. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer. 2016 Mar 1;16:172.
2.Yao W, et al. Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Lett. 2015 Aug 1;364(1):70-8.
3.SS Bhagwat, et al. Annu Rep Med Chem, 2007, 42, 265–278.
4.Serra V, et al. J Clin Invest, 2013, 123(6), 2551-2563.
5.Cheng H, et al. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35(23):2961-70.
6.Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7(15):19997-20015.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2